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Reply to: ''Pre-retrieval reperfusion decreases cancer recurrence after rat ischemic liver graft transplantation''
To the Editor:
We thank Drs Cheng and Lv [1] for their interest in our work suggesting an increased rate of hepatocellular carcinoma (HCC) recurrence/growth after transplantation of ischemic liver grafts, and the protective effect of in situ graft reperfusion prior to retrieval [2] . Our rat transplantation model only approximates clinical reality. It used liver grafts undergoing 10 or 30 min of ischemia prior to retrieval (clamping the porta hepatis and the infra-hepatic vena cava in the donor). HCC cells were injected intra-portally, and liver HCC volumes were repeatedly assessed by magnetic resonance imaging. A two-hour donor liver reperfusion prior to retrieval was reversing the effects of ischemia/reperfusion and was associated to lower rates of post-transplant HCC growth.
Normothermic extracorporeal membrane oxygenation (NEC-MO) is the closest clinical procedure to reproduce the studied model, as it allows restoring the perfusion of the donor organs in case of donation after cardiac death (DCD). Apart from being primed with a perfusion solution, NECMO uses the donor's own blood, with a maintained pH between 7.0 and 7.4 [3] . However, it is currently unknown whether NECMO can also have a protective impact on post-transplant HCC recurrence/growth, and this Journal of Hepatology 2014 vol. 61 j 962-966
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field deserves further assessment. Similarly, ex situ machine perfusion, either normothermic, hypothermic or sub-normothermic has confirmed protective effects on liver ischemia/reperfusion lesions, but its impact on cancer has never been tested [4] [5] [6] [7] [8] .
The minimal required time of liver graft reperfusion for preventing HCC growth is currently unknown. The used two-hour reperfusion matches international reports with NECMO or ex situ machine perfusion ranging between one and four hours [3, 7, 8] . It is also in agreement with the need for a minimal two-hour graft normothermic machine reperfusion in order to restore the function of ischemic rat livers [4] .
Overall, ischemia/reperfusion may be an added factor altering post-transplant cancer recurrence. This link is likely weaker than the one between pre-transplant HCC characteristics and recurrence, but it deserves further exploration both to better understand the underlying mechanisms and the ways to prevent it.
Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors
To the Editor: After liver transplantation (LT), immunosuppression with mammalian target-of-rapamycin (mTOR) inhibitors without calcineurin inhibitors (CNIs) is used to preserve kidney function [1] , and because of its anti-neoplastic effect, particularly for patients who have a history of hepatocellular carcinoma [2] . However, in kidney-transplant patients, this immunosuppressive strategy has been associated with an increased risk of developing donorspecific antibodies (DSAs) [3] . After a LT, although the impact of the occurrence of de novo DSAs on short-and long-term outcomes is still controversial [4] , de novo DSAs are associated with an increased risk of antibody-mediated rejection [5] , chronic rejection [6] [7] [8] , and anastomotic biliary stricture [9]. However, because the incidence of de novo DSAs using the Luminex assay in liver-transplant patients receiving mTOR inhibitor-based immunosuppression is unknown, this was the aim of this retrospective study. Between 2008 and 2013, 394 liver-transplant patients were followed-up in our institution. Of these, 61 patients were receiving an mTOR inhibitor (6.5%). Five of the 61 patients were excluded from the study: four because they had not undergone anti-HLA screening after conversion to mTOR inhibitors, and one patient because he received both CNIs and mTOR inhibitors. Hence, 56 liver-transplant patients, converted from CNIs to mTOR inhibitors, were included in this study (Table 1 ). Twelve patients had undergone an abrupt conversion from CNIs to sirolimus and 44 patients had undergone progressive conversion to everolimus. The target trough (C0) levels for sirolimus and everolimus were 6-10 ng/ml. The median time between conversion to mTOR inhibitors and the last follow-up was 28 (range: 2-102) months.
